

SBI HOLDINGS, INC.

(Incorporated in Japan with limited liability)

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED MARCH 31, 2021

The board of directors (the “Directors”) of SBI HOLDINGS, INC. (the “Company”) is pleased to announce the consolidated results of the Company and its subsidiaries (collectively the “Group”) for the year ended March 31, 2021.

(Amounts are rounded to the nearest million Japanese yen)

1. Consolidated Financial Results

(1) Consolidated Operating Results

(Percentages represent year-on-year changes)

	Revenue		Profit before income tax expense		Profit for the year		Profit attributable to owners of the Company	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Fiscal year ended March 31, 2021	541,145	47.0	140,380	113.3	97,512	116.7	81,098	116.3
Fiscal year ended March 31, 2020	368,055	4.7	65,819	(20.7)	45,000	(33.1)	37,487	(28.7)

	Total comprehensive income		Basic earnings per share attributable to owners of the Company	Diluted earnings per share attributable to owners of the Company
	Millions of yen	%	Yen	Yen
Fiscal year ended March 31, 2021	122,187	479.3	339.78	296.92
Fiscal year ended March 31, 2020	21,091	(66.7)	163.18	147.44

	Ratio of profit to equity attributable to owners of the Company	Ratio of profit before income tax expense to total assets	Ratio of operating income to operating revenue
	%	%	%
Fiscal year ended March 31, 2021	16.0	2.2	25.9
Fiscal year ended March 31, 2020	8.3	1.2	17.9

(Note) Share of results of associates Fiscal year ended March 31, 2021: 9,458 million yen
Fiscal year ended March 31, 2020: 6,527 million yen

(2) Consolidated Financial Position

	Total assets	Total equity	Equity attributable to owners of the Company	Ratio of equity attributable to owners of the Company to total assets	Equity per share attributable to owners of the Company
	Millions of yen	Millions of yen	Millions of yen	%	Yen
March 31, 2021	7,208,572	717,095	562,116	7.8	2,297.87
March 31, 2020	5,513,227	593,699	451,476	8.2	1,955.91

(3) Consolidated Cash Flows

	Operating activities	Investing activities	Financing activities	Cash and cash equivalents at the end of the year
	Millions of yen	Millions of yen	Millions of yen	Millions of yen
Fiscal year ended March 31, 2021	(178,403)	(82,071)	210,822	802,702
Fiscal year ended March 31, 2020	26,849	(70,887)	181,626	843,755

2. Dividends

(Declared date)	Dividend per share					Total dividend (annual)	Payout ratio (cons.)	Ratio of dividend to equity attributable to owners of the Company (cons.)
	End of 1 st Q	End of 2 nd Q	End of 3 rd Q	Year-end	Full year			
	Yen	Yen	Yen	Yen	Yen	Millions of yen	%	%
Fiscal year ended March 31, 2020	—	20.00	—	80.00	100.00	23,077	61.3	5.1
Fiscal year ended March 31, 2021	—	20.00	—	100.00	120.00	29,324	35.3	5.6
Fiscal Year ending March 31, 2022 (forecast) (Note)	—	—	—	—	—		—	

(Note) Fiscal year ending March 31, 2022 forecast is to be determined.

3. Total number of shares outstanding (Common stock)

- (1) Number of shares outstanding (including treasury stock) : March 31, 2021 : 244,639,390shares
: March 31, 2020 : 236,556,393shares
- (2) Number of treasury stock : March 31, 2021 : 15,084shares
: March 31, 2020 : 5,730,038shares
- (3) Average number of shares outstanding : Year ended March 31, 2021 : 238,676,048shares
: Year ended March 31, 2020 : 229,724,077shares

The Group prepared the consolidated financial statements in accordance with IFRSs.

(Reference Information)
Non-consolidated Financial Results

(1) Non-consolidated Operating Results

(Percentages represent year-on-year changes)

	Net sales		Operating income		Ordinary income		Net income	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Fiscal year ended March 31, 2021	88,901	178.4	70,786	446.7	69,573	632.5	23,499	114.9
Fiscal year ended March 31, 2020	31,937	16.9	12,947	62.9	9,498	365.6	10,938	100.4

	Net income per share	Diluted net income per share
	Yen	Yen
Fiscal year ended March 31, 2021	98.46	84.11
Fiscal year ended March 31, 2020	47.61	41.28

(2) Non-consolidated Financial Position

	Total assets	Net assets	Ratio of shareholder's equity to total assets	Net assets per share
	Millions of yen	Millions of yen	%	Yen
March 31, 2021	1,085,970	392,485	36.0	1,598.81
March 31, 2020	894,301	351,074	39.1	1,515.98

(Note) Shareholders' equity

Fiscal year ended March 31, 2021: 391,107 million yen
 Fiscal year ended March 31, 2020: 349,927 million yen

The non-consolidated financial results were prepared in accordance with JGAAP.

This financial summary is not subject to audit.

1. BUSINESS RESULTS

(1) Overview of Business Results for the Fiscal Year

The Group's consolidated results of operations for the fiscal year ended March 31, 2021 were as follow. Revenue increased 47.0% year-on-year to ¥541,145 million, profit before income tax expense increased 113.3% to ¥140,380 million, and profit attributable to owners of the Company increased 116.3% to ¥81,098 million.

The results of operations for each reporting segment of the Group for the fiscal year ended March 31, 2021 were as follow.

The Group changed the reporting segment name "Biotechnology-related Business" to "Biotechnology, Healthcare & Medical Informatics Business" from the third quarter ended December 31, 2020. SBI Leasing Services Co., Ltd., which was included in the Financial Services Business until the previous reporting period, and SBI Crypto Investment Co., Ltd., which was included in the Others until the previous reporting period, are now included in the Asset Management Business beginning with this fiscal year. SBI CapitalBase Co., Ltd., which was included in the Others until the previous reporting period and changed its company name to SBI Equity Crowd Co., Ltd. on July 1, 2020, is now included in the Financial Services Business beginning with this fiscal year. Consequently, segment information for the year ended March 31, 2020, is restated in accordance with the new basis of segmentation.

	Revenue			Profit before income tax expense		
	Fiscal year ended March 31, 2020	Fiscal year ended March 31, 2021		Fiscal year ended March 31, 2020	Fiscal year ended March 31, 2021	
	Millions of Yen	Millions of Yen	%	Millions of Yen	Millions of Yen	%
Financial Services Business	236,751	311,724	31.7	51,275	85,755	67.2
Asset Management Business	126,585	208,332	64.6	37,230	84,853	127.9
Biotechnology, Healthcare & Medical Informatics Business	3,920	5,627	43.5	(11,431)	(8,630)	—
Total	367,256	525,683	43.1	77,074	161,978	110.2
Others	5,226	21,740	316.0	(1,733)	(10,595)	—
Elimination or Corporate	(4,427)	(6,278)	—	(9,522)	(11,003)	—
Consolidated Total	368,055	541,145	47.0	65,819	140,380	113.3

(% represents year-on-year changes)

(Financial Services Business)

The Financial Services Business consists of a wide range of finance-related business, including securities brokerage business, banking services business and life, property and casualty insurance business.

The results of operations of the Financial Services Business for the fiscal year ended March 31, 2021 were as follows. Revenue increased 31.7% year-on-year to ¥311,724 million, and profit before income tax expense increased 67.2% to ¥85,755 million. This was mainly due to higher sales and profits in the securities business as a result of favorable stock market conditions compared to the previous fiscal year.

(Asset Management Business)

The Asset Management Business primarily consists of fund management and investment in Internet technology, fintech, blockchain, finance, and biotechnology-related venture companies in Japan and overseas, financial services business overseas, and asset management services business which provides financial products information.

The results of operations of the Asset Management Business for the fiscal year ended March 31, 2021 were as follows. Revenue increased 64.6% year-on-year to ¥208,332 million, and profit before income tax expense increased 127.9% year-on-year to ¥84,853 million. This was mainly due to an increase in "Income arising from financial assets measured at FVTPL" recognized on investments in companies.

(Biotechnology, Healthcare & Medical Informatics Business)

The Biotechnology, Healthcare & Medical Informatics Business represents development and distribution of pharmaceutical products, health foods, and cosmetics with 5-aminolevulinic acid (ALA*), a kind of amino acid which exists in vivo, research and development of antibody drugs and nucleic acid medicine in the field of cancer and immunology, the digitization of medical and health information, providing solutions and services that promote and the use of medical big data, and medical finance.

The results of operations of the Biotechnology, Healthcare & Medical Informatics Business for the fiscal year ended March 31, 2021 were as follows. Revenue increased 43.5% year-on-year to ¥5,627 million, and loss before income tax expense amounted to ¥8,630 million for the fiscal year ended March 31, 2021 (¥11,431 million of loss before income tax expense for the fiscal year ended March 31, 2020).

* Five-aminolevulinic acid (ALA) is an amino acid generated by mitochondria in the human body and an important substance used to produce heme or cytochrome, proteins to generate energy. The production of ALA in the human body decreases with age. ALA is included in food products, including slops of distilled spirits, red wine, and Asian ginseng. ALA is also known as a chloroplastic substance in plants.

(2) Overview of Financial Conditions for the Fiscal Year

As at March 31, 2021, total assets amounted to ¥7,208,572 million and increased by ¥1,695,345 million from total assets of ¥5,513,227 million as at March 31, 2020. The Group's equity increased by ¥123,396 million to ¥717,095 million from the fiscal year ended March 31, 2020. As at March 31, 2021, the Group's cash and cash equivalents amounted to ¥802,702 million and decreased by ¥41,053 million from that of ¥843,755 million as at March 31, 2020. The changes of cash flows for each activity and the reasons for changes are as follows:

(Operating Cash Flows)

Cash flows from operating activities amounted to ¥178,403 million in net cash outflows (¥26,849 million in net cash inflows for the year ended March 31, 2020). The net cash outflows were primarily due to a ¥246,508 million cash outflow from an increase in trade and other accounts receivables, a ¥221,904 million cash outflow from an increase in assets/liabilities related to securities business and a ¥131,448 million cash outflow from an increase in operational investment securities, despite a ¥220,081 million cash inflow from an increase in customer deposits in the banking business and a ¥140,380 million cash inflow from a profit before income tax expense.

(Investing Cash Flows)

Cash flows from investing activities amounted to ¥82,071 million in net cash outflows (¥70,887 million in net cash outflows for the year ended March 31, 2020). The net cash outflows were primarily due to a ¥77,392 million cash outflow from purchases of investment securities and a ¥70,172 million cash outflow from payments of loans receivable, despite a ¥49,860 million cash inflow from collection of loans receivable.

(Financing Cash Flows)

Cash flows from financing activities amounted to ¥210,822 million in net cash inflows (¥181,626 million in net cash inflows for the year ended March 31, 2020). The net cash inflows were primarily due to a ¥228,124 million cash inflow from proceeds from issuance of bonds payable and a ¥69,808 million cash inflow from an increase in short term loans payable, despite a ¥112,576 million cash outflow from redemption of bonds payable.

2. THE BASIC CONCEPT REGARDING SELECTION OF ACCOUNTING STANDARDS

The Group applied IFRS from the fiscal year ended March 31, 2013 in order to improve the international comparability of financial information in the capital markets.

3. CONSOLIDATED FINANCIAL STATEMENTS AND NOTES

(1) Consolidated Statement of Financial Position

	As at March 31, 2020	As at March 31, 2021
	Millions of Yen	Millions of Yen
Assets		
Cash and cash equivalents	843,755	802,702
Trade and other accounts receivable	822,131	1,183,896
Assets related to securities business		
Cash segregated as deposits	1,726,040	2,292,743
Margin transaction assets	495,997	972,573
Other assets related to securities business	576,501	631,305
Total assets related to securities business	2,798,538	3,896,621
Other financial assets	40,994	58,715
Operational investment securities	394,923	528,154
Other investment securities	180,444	209,545
Investments accounted for using the equity method	63,657	103,807
Property and equipment	51,857	64,290
Intangible assets	190,278	225,607
Other assets	116,765	123,071
Deferred tax assets	9,885	12,164
Total assets	5,513,227	7,208,572
Liabilities		
Bonds and loans payable	1,149,050	1,394,137
Trade and other accounts payable	76,977	189,729
Liabilities related to securities business		
Margin transaction liabilities	150,699	269,152
Loans payable secured by securities	351,701	602,921
Deposits from customers	959,773	1,277,808
Guarantee deposits received	819,838	961,651
Other liabilities related to securities business	392,347	410,270
Total liabilities related to securities business	2,674,358	3,521,802
Customer deposits for banking business	734,221	1,042,132
Insurance contract liabilities	141,898	150,123
Income tax payable	11,373	20,125
Other financial liabilities	23,083	30,333
Other liabilities	88,925	107,301
Deferred tax liabilities	19,643	35,795
Total liabilities	4,919,528	6,491,477
Equity		
Capital stock	92,018	98,711
Capital surplus	139,993	147,753
Treasury stock	(13,874)	(40)
Other components of equity	(6,385)	18,197
Retained earnings	239,724	297,495
Equity attributable to owners of the Company	451,476	562,116
Non-controlling interests	142,223	154,979
Total equity	593,699	717,095
Total liabilities and equity	5,513,227	7,208,572

(2) Consolidated Statements of Income and Comprehensive Income
Consolidated Statement of Income

	Fiscal year ended March 31, 2020	Fiscal year ended March 31, 2021
	Millions of Yen	Millions of Yen
Revenue (Interest income of ¥118,779 million and ¥143,364 million included for the year ended March 31, 2020 and 2021, respectively)	368,055	541,145
Expense		
Financial cost associated with financial income	(25,186)	(26,773)
Provision for credit losses	(31,567)	(41,147)
Operating cost	(110,696)	(142,519)
Selling, general and administrative expenses	(132,226)	(163,326)
Other financial cost	(5,140)	(5,803)
Other expenses	(3,948)	(30,655)
Total expense	<u>(308,763)</u>	<u>(410,223)</u>
Share of the profit of associates and joint ventures accounted for using the equity method	6,527	9,458
Profit before income tax expense	<u>65,819</u>	<u>140,380</u>
Income tax expense	(20,819)	(42,868)
Profit for the year	<u>45,000</u>	<u>97,512</u>
Profit for the year attributable to		
Owners of the Company	37,487	81,098
Non-controlling interests	7,513	16,414
Profit for the year	<u>45,000</u>	<u>97,512</u>
Earnings per share attributable to owners of the Company		
Basic (Yen)	163.18	339.78
Diluted (Yen)	147.44	296.92

Consolidated Statement of Comprehensive Income

	Fiscal year ended March 31, 2020	Fiscal year ended March 31, 2021
	Millions of Yen	Millions of Yen
Profit for the year	45,000	97,512
Other comprehensive income		
Items that will not be reclassified subsequently to profit or loss		
Equity instruments measured at FVTOCI	(639)	(18)
Share of other comprehensive income of associates and joint ventures accounted for using the equity method	(384)	109
	<u>(1,023)</u>	<u>91</u>
Items that may be reclassified subsequently to profit or loss		
Debt instruments measured at FVTOCI	349	(168)
Currency translation differences	(19,807)	23,871
Share of other comprehensive income of associates and joint ventures accounted for using the equity method	(3,428)	881
	<u>(22,886)</u>	<u>24,584</u>
Other comprehensive income, net of tax	(23,909)	24,675
Total comprehensive income	<u>21,091</u>	<u>122,187</u>
Total comprehensive income attributable to		
Owners of the Company	13,519	105,680
Non-controlling interests	7,572	16,507
Total comprehensive income	<u>21,091</u>	<u>122,187</u>

(3) Consolidated Statement of Changes in Equity

	Attributable to owners of the Company						Non-controlling interests	Total equity
	Capital stock	Capital surplus	Treasury stock	Other components of equity	Retained earnings	Total		
	Millions of Yen	Millions of Yen	Millions of Yen	Millions of Yen	Millions of Yen	Millions of Yen		
As at April 1, 2019	92,018	142,094	(20,128)	16,977	225,714	456,675	105,882	562,557
Profit for the year	-	-	-	-	37,487	37,487	7,513	45,000
Other comprehensive income	-	-	-	(23,968)	-	(23,968)	59	(23,909)
Total comprehensive income	-	-	-	(23,968)	37,487	13,519	7,572	21,091
Conversion of convertible bonds	-	(1,496)	4,821	-	-	3,325	-	3,325
Change in scope of consolidation	-	-	-	-	-	-	(4,476)	(4,476)
Dividends paid	-	-	-	-	(22,871)	(22,871)	(13,701)	(36,572)
Treasury shares purchased	-	-	(16)	-	-	(16)	-	(16)
Treasury shares sold	-	(514)	1,449	-	-	935	-	935
Share-based payment transactions	-	225	-	-	-	225	583	808
Changes of interests in subsidiaries without losing control	-	(316)	-	-	-	(316)	46,363	46,047
Transfer	-	-	-	606	(606)	-	-	-
As at March 31, 2020	92,018	139,993	(13,874)	(6,385)	239,724	451,476	142,223	593,699
Profit for the year	-	-	-	-	81,098	81,098	16,414	97,512
Other comprehensive income	-	-	-	24,582	-	24,582	93	24,675
Total comprehensive income	-	-	-	24,582	81,098	105,680	16,507	122,187
Issuance of new shares	2,652	2,271	-	-	-	4,923	-	4,923
Issuance of convertible bonds	-	2,756	-	-	-	2,756	-	2,756
Conversion of convertible bonds	4,041	(484)	12,805	-	-	16,362	-	16,362
Change in scope of consolidation	-	-	-	-	-	-	(9,788)	(9,788)
Dividends paid	-	-	-	-	(23,327)	(23,327)	(15,018)	(38,345)
Treasury shares purchased	-	-	(39)	-	-	(39)	-	(39)
Treasury shares sold	-	(378)	1,068	-	-	690	-	690
Share-based payment transactions	-	799	-	-	-	799	(5)	794
Changes of interests in subsidiaries without losing control	-	2,796	-	-	-	2,796	21,060	23,856
As at March 31, 2021	98,711	147,753	(40)	18,197	297,495	562,116	154,979	717,095

(4) Consolidated Statement of Cash flows

	Fiscal year ended March 31, 2020	Fiscal year ended March 31, 2021
	Millions of Yen	Millions of Yen
Cash flows from operating activities		
Profit before income tax expense	65,819	140,380
Depreciation and amortization	15,904	24,291
Share of profits of associates and joint ventures accounted for using the equity method	(6,527)	(9,458)
Interest and dividend income	(123,412)	(150,325)
Interest expense	30,318	32,573
Increase in operational investment securities	(114,172)	(131,448)
Increase in trade and other accounts receivables	(146,427)	(246,508)
Increase in trade and other accounts payable	5,711	88,237
Decrease (Increase) in assets/liabilities related to securities business	78,095	(221,904)
Increase in customer deposits in the banking business	139,580	220,081
Others	775	(17,223)
Subtotal	(54,336)	(271,304)
Interest and dividend income received	125,116	145,959
Interest paid	(28,214)	(29,281)
Income taxes paid	(15,717)	(23,777)
Net cash generated (used in) from operating activities	26,849	(178,403)
Cash flows from investing activities		
Purchases of intangible assets	(14,250)	(15,419)
Purchases of investment securities	(36,885)	(77,392)
Proceeds from sales or redemption of investment securities	39,404	40,735
Acquisition of subsidiaries, net of cash and cash equivalents acquired	(10,077)	(8,026)
Payments of loans receivable	(50,303)	(70,172)
Collection of loans receivable	24,431	49,860
Others	(23,207)	(1,657)
Net cash used in investing activities	(70,887)	(82,071)

	Fiscal year ended March 31, 2020	Fiscal year ended March 31, 2021
	Millions of Yen	Millions of Yen
Cash flows from financing activities		
Increase in short term loans payable	26,604	69,808
Proceeds from long-term loans payable	58,043	54,936
Repayment of long-term loans payable	(37,948)	(21,953)
Proceeds from issuance of bonds payable	179,889	228,124
Redemption of bonds payable	(46,626)	(112,576)
Proceeds from issuance of shares	-	4,923
Proceeds from stock issuance to non-controlling interests	5,354	6,356
Contributions from non-controlling interests in consolidated investment funds	35,646	15,572
Cash dividends paid	(22,860)	(23,313)
Cash dividends paid to non-controlling interests	(718)	(763)
Distributions to non-controlling interests in consolidated investment funds	(13,008)	(14,243)
Purchase of treasury stock	(14)	(39)
Proceeds from sale of interests in subsidiaries to non-controlling interests	302	9,223
Payments for purchase of interests in subsidiaries from non-controlling interests	(50)	(155)
Others	(2,988)	(5,078)
Net cash generated from financing activities	<u>181,626</u>	<u>210,822</u>
Net increase (decrease) in cash and cash equivalents	137,588	(49,652)
Cash and cash equivalents at the beginning of the year	713,974	843,755
Effect of changes in exchange rate on cash and cash equivalents	(7,807)	8,599
Cash and cash equivalents at the end of the year	<u><u>843,755</u></u>	<u><u>802,702</u></u>

(5) Notes to Consolidated Financial Statements

1. Segment Information

The Group engages in a wide range of business activities, primarily online financial service businesses and investment activities in Japan and overseas. Based on the similarities or economic characteristics of business or nature of services, "Financial Services Business", "Asset Management Business", and "Biotechnology, Healthcare & Medical Informatics Business", which is anticipated to be a growth industry in the 21st century, are determined as reportable segments.

The reportable segments of the Group represent businesses activities for which separate financial information of the Group's components is available and reviewed regularly by the board of directors for the purpose of allocation of financial resources and performance evaluation.

The following is a description of business activities for the reporting segments.

The Group changed the reporting segment name "Biotechnology-related Business" to "Biotechnology, Healthcare & Medical Informatics Business" from the third quarter ended December 31, 2020.

"Financial Services Business"

The Financial Services Business consists of a wide range of finance-related business, including securities brokerage business, banking services business, and life, property and casualty insurance business.

"Asset Management Business"

The Asset Management Business primarily consists of fund management and investment in Internet technology, fintech, blockchain, finance, and biotechnology-related venture companies in Japan and overseas, financial services business overseas, and asset management services business which provides financial products information.

"Biotechnology, Healthcare & Medical Informatics Business"

The Biotechnology, Healthcare & Medical Informatics Business represents development and distribution of pharmaceutical products, health foods, and cosmetics with 5-aminolevulinic acid (ALA*), a kind of amino acid which exists in vivo, research and development of antibody drugs and nucleic acid medicine in the field of cancer and immunology, the digitization of medical and health information, providing solutions and services that promote and the use of medical big data, and medical finance.

"Others" includes the digital asset-related business, the real estate business, the renewable energy business and other businesses, but they did not meet the quantitative criteria to be defined as reportable segments for the fiscal year ended March 31, 2021.

"Elimination or Corporate" includes profit or loss that is not allocated to certain business segments and the elimination of the inter-company transactions within the Group, at a price based on the actual market price.

The following represents segment information of the Group:

SBI Leasing Services Co., Ltd., which was included in the Financial Services Business until the previous reporting period, and SBI Crypto Investment Co., Ltd., which was included in the Others until the previous reporting period, are now included in the Asset Management Business beginning with this fiscal year. SBI CapitalBase Co., Ltd., which was included in the Others until the previous reporting period and changed its company name to SBI Equity Crowd Co., Ltd. on July 1, 2020, is now included in the Financial Services Business beginning with this fiscal year. Consequently, segment information for the year ended March 31, 2020, is restated in accordance with the new basis of segmentation.

For the year ended March 31, 2020

	Financial Services Business	Asset Management Business	Biotechnology, Healthcare & Medical Informatics Business	Total	Others	Elimination	Consolidated Total
	Millions of Yen	Millions of Yen	Millions of Yen	Millions of Yen	Millions of Yen	Millions of Yen	Millions of Yen
Revenue	236,751	126,585	3,920	367,256	5,226	(4,427)	368,055
Profit (loss) before income tax expense	51,275	37,230	(11,431)	77,074	(1,733)	(9,522)	65,819

For the year ended March 31, 2021

	Financial Services Business	Asset Management Business	Biotechnology, Healthcare & Medical Informatics Business	Total	Others	Elimination	Consolidated Total
	Millions of Yen	Millions of Yen	Millions of Yen	Millions of Yen	Millions of Yen	Millions of Yen	Millions of Yen
Revenue	311,724	208,332	5,627	525,683	21,740	(6,278)	541,145
Profit (loss) before income tax expense	85,755	84,853	(8,630)	161,978	(10,595)	(11,003)	140,380

2. Revenue

	Fiscal year ended March 31, 2020	Fiscal year ended March 31, 2021
	Millions of yen	Millions of yen
Financial income		
Interest income		
Income arising from financial assets measured at amortized cost (Note 1)	117,992	142,628
Income arising from debt instruments measured at FVTOCI (Note 2)	787	736
Income arising from financial assets measured at FVTPL	48,723	133,532
Others	184	576
Total financial income	167,686	277,472
Revenue arising on insurance contracts	87,517	96,301
Revenue from contracts with customers		
Revenue from rendering of services	83,187	105,431
Revenue from sales of goods	6,014	14,898
Others	23,651	47,043
Total revenue	368,055	541,145

(Note 1) Interest income arising from loans in the banking and securities businesses.

(Note 2) Interest income arising from bonds in the insurance business.

3. Earnings per Share

The basic and diluted earnings per share attributable to owners of the Company are calculated based on the following information.

	Fiscal year ended March 31, 2020	Fiscal year ended March 31, 2021
	Millions of yen	Millions of yen
Earnings		
Profit attributable to owners of the Company	37,487	81,098
Dilutive effect: Convertible bonds	374	664
Profit attributable to owners of the Company after dilutive effect	37,861	81,762
Shares	Shares	Shares
Basic weighted average number of ordinary shares	229,724,077	238,676,048
Dilutive effect: Stock options	1,969,058	2,244,040
Dilutive effect: Convertible bonds	25,094,962	34,445,617
Weighted average number of ordinary shares after the dilutive effect	256,788,097	275,365,705
Earnings per share attributable to owners of the Company	Yen	Yen
Basic	163.18	339.78
Diluted	147.44	296.92

4. Events after the Reporting Period

There was no significant event after the reporting period.